Immunooncology spinout Neoleukin Therapeutics is working on a safer, synthetic replica of a T-cell-boosting protein called interleukin-2.

University of Washington has officially unveiled US-based spinout Neoleukin Therapeutics to commercialise an immunooncology drug that will aim to bolster the patient’s T-cell receptors, GeekWire reported yesterday.
Founded in November 2018, Neoleukin is aiming to develop a synthetic version of an immuno-stimulating protein called interleukin-2 (IL-2) that enhances the patient’s T-cell receptors so that they can detect and destroy malignant cancerous cells.
IL-2 is already prescribed for its cytotoxic – cancer killing – properties in melanoma and renal cell carcinoma, however the protein’s applicability is currently limited by harsh side effects.
Neoleukin’s first candidate, Neo-2/15, is designed to bind to the two T-cell receptors that offer cytotoxic benefit without triggering a third receptor associated with damaging effects.
The drug has already shown promise in pre-clinical trials and will initially be tried out as a safer replacement for melanoma and renal cell carcinoma IL-2 therapies.
Neo-2/15 was…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?